Drug Trial Radar · NCT05497336
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Aug 18, 2022
Primary completion
Jan 24, 2025
Study completion Jan 24, 2025
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1b consists of combined dose escalation phase and dose expansion phase. Phase 3 study will compare efficacy and safety of IBI351 combined with cetuximab versus chemotherapy in treatment of KRAS G12C-mutated metastatic colorectal cancer
Conditions
- Colorectal Cancer
Interventions
IBI351Drug
IBI351 is administered orally
CetuximabDrug
Cetuximab is administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTs (Dose-limiting Toxicity) in the Combined Dose Escalation PhaseTime frame: 28 days during the first 4-week cycle
- Objective response rate (ORR)Time frame: Up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.